Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Pharmacological profile of the abeorphine 201-678, a potent orally active and long lasting dopamine agonist

Journal Article · · Life Sci.; (United States)
The central dopaminergic effects of an abeorphine derivative 201-678 were compared to those of apomorphine and bromocriptine in different model systems. After oral administration, this compound induced contralateral turning in rats with 6-hydroxydopamine induced nigral lesions and exhibited strong anti-akinetic properties in rats with 6-hydroxydopamine induced hypothalamic lesions. It decreased dopamine metabolism in striatum and cortex, but did not modify noradrenaline and serotonin metabolism in the rat brain. 201-678 counteracted the in vivo increase of tyrosine hydroxylase activity induced by ..gamma..-butyrolactone. In vitro it stimulated DA-sensitive adenylate cyclase and inhibited acetylcholine release from rat striatal slices. This compound had high affinity for /sup 3/H-dopamine and /sup 3/H-clonidine binding sites. These results indicate that 201-678 is a potent, orally active dopamine agonist with a long duration of action. Furthermore it appears more selective than other dopaminergic drugs. 29 references, 5 figures, 3 tables.
Research Organization:
Sandoz Ltd., Basel, Switzerland
OSTI ID:
6381429
Journal Information:
Life Sci.; (United States), Journal Name: Life Sci.; (United States) Vol. 38:2; ISSN LIFSA
Country of Publication:
United States
Language:
English

Similar Records